Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ASPH | Q12797 | 2/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31281607 | 1.00 | NAPRT (0.46) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL28280472 | 0.83 | KDM4E (0.38) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL2674661 | 0.82 | NAPRT (0.36) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL15549181 | 0.82 | NAPRT (0.36) | NAPRTKDM4EASPHKDM8MAPT | |
| SCHEMBL26618917 | 0.82 | NAPRT (0.36) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL2114463 | 0.79 | NAPRT (0.48) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL3516266 | 0.78 | CA12 (0.40) | KDM4EALDH1A1KDM3AKDM6BKDM5C | |
| SCHEMBL29004701 | 0.78 | FFAR1 (0.35) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL30634909 | 0.78 | GAA (0.37) | NAPRTKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL26618864 | 0.78 | GAA (0.37) | NAPRTKDM4EASPHKDM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250250293-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-07-03 | — | — | US | disclosed |
| WO-2025088571-A1 | CRYSTALLINE FORMS OF TEAD INHIBITOR | ASTRAZENECA AB (SE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4514793-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| EP-4486750-A1 | INHIBITORS OF MEK KINASE | Kinnate Biopharma Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119156385-A | Fused bicyclic heteroaromatic compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12122800-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122800-B2 | Inhibitors of MEK kinase | BRAF, NRAS, RAF1 | NAPRT 1960/4885KDM4E 940/4885ASPH 3099/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | NAPRT 1433/4885KDM4E 936/4885ASPH 1852/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | NAPRT 467/4885KDM4E 3651/4885ASPH 29/4885 |
| US-20250250293-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | NAPRT 1960/4885KDM4E 940/4885ASPH 3099/4885 |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA | NAPRT 2134/4885KDM4E 2306/4885ASPH 1496/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | NAPRT 467/4885KDM4E 3651/4885ASPH 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.